Intraventricular hemorrhage > Grade II: 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in intraventricular hemorrhage > Grade II: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 5: 0.2 mg IV versus 0.2 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 5: 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25: 0.2 mg IV versus 0.2 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Necrotizing enterocolitis ‐ 0.2 mg IV versus 0.2 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in necrotizing enterocolitis ‐ 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Global: Discontinuation of Vitamin B6 · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Discontinuation of Vitamin B6 compared with placebo (low certainty).
1 finding from 1 review
Progression to late AMD (neovascular AMD, geographic atrophy or both) · people with AMD
It is very uncertain whether vitamin E changes progression to late AMD (neovascular AMD, geographic atrophy or both) compared with placebo (very low certainty).
1 finding from 1 review
Progression to neovascular AMD · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression to geographic atrophy · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Vitamin E showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (low certainty).
1 finding from 1 review
Quality of life · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · people with AMD
It is very uncertain whether vitamin E changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
4 participants
Very low
Resource use and costs · people with AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution of acute illness · children with acute pneumonia
1 finding from 1 review
Number of days in hospital (duration of hospitalisation) · children with acute pneumonia
1 finding from 1 review
Mortality rate ( · children with acute pneumonia
Vitamin D showed no clear difference in mortality rate ( compared with placebo (low certainty).
1 finding from 1 review
Quality of life · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vertebral fracture · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐vertebral fractures · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found